FDA grants BTX 1801 QIDP designation
Australian dermatology specialist Botanix Pharmaceuticals (ASX: BOT) today announced the US Food and Drug Administration has granted a Qualified Infectious Disease Product (QIDP) designation for its first antibacterial platform product, BTX 1801, with the news sending the firm’s shares rocketing 61.76% to A$0.055.
BTX 1801 is the first cannabinoid-based program to receive the designation, which represents a strong endorsement of the data we have collected to date. The company’s focus is currently on preventing post-surgical infections, but it hopes to test the capabilities of synthetic cannabinoid for fighting antibiotic resistance more broadly too – a major global issue in healthcare.
Potential to prevent post-surgical infections
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze